Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug 1;153(8):760-764.
doi: 10.1001/jamadermatol.2017.0201.

Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States

Amit Garg  1 , Joslyn S Kirby  2 , Jonathan Lavian  1 , Gloria Lin  1 , Andrew Strunk  1
Affiliations

Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States

Amit Garg et al. JAMA Dermatol. .

Abstract

Importance: The true prevalence of hidradenitis suppurativa (HS) is unknown.

Objective: To establish standardized overall and group-specific prevalence estimates for HS in the United States.

Design, setting, and participants: This retrospective analysis included a demographically heterogeneous population-based sample of more than 48 million unique patients across all US census regions. As of October 27, 2016, a total of 47 690 patients with HS were identified using electronic health record data.

Main outcomes and measures: Standardized overall point prevalence for HS and sex-, age-, and race-specific prevalence estimates of HS in the general US population.

Results: Of the 47 690 patients with HS (26.2% men and 73.8% women), the overall HS prevalence in the US population sample was 0.10%, or 98 per 100 000 persons (95% CI, 97-99 per 100 000 persons). The adjusted prevalence in women was 137 per 100 000 (95% CI, 136-139 per 100 000), more than twice that of men (58 per 100 000; 95% CI, 57-59 per 100 000; P < .001). The prevalence of HS was highest among patients aged 30 to 39 years (172 per 100 000; 95% CI, 169-275 per 100 000) compared with all other age groups (range, 15-150 per 100 000; P < .001). Adjusted HS prevalences among African American (296 per 100 000; 95% CI, 291-300 per 100 000) and biracial (218 per 100 000; 95% CI, 202-235 per 100 000) patients were more than 3-fold and 2-fold greater, respectively, than that among white patients (95 per 100 000; 95% CI, 94-96 per 100 000; P < .001).

Conclusions and relevance: Hidradenitis suppurativa is an uncommon, but not rare, disease in the United States that disproportionately affects female patients, young adults, and African American and biracial patients.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Drs Garg and Kirby report serving as advisors for and receiving honoraria from AbbVie. No other disclosures were reported.

References

    1. Lookingbill DP. Yield from a complete skin examination: findings in 1157 new dermatology patients. J Am Acad Dermatol. 1988;18(1, pt 1):31-37. - PubMed
    1. Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35(2, pt 1):191-194. - PubMed
    1. Jemec GB. The symptomatology of hidradenitis suppurativa in women. Br J Dermatol. 1988;119(3):345-350. - PubMed
    1. von der Werth JM, Williams HC. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2000;14(5):389-392. - PubMed
    1. Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. . Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59(4):596-601. - PubMed

MeSH terms